Nigel Keith Davis
Directeur/Membre du Conseil chez Pronec Ltd.
Profil
Nigel Keith Davis is currently a Director at Pronec Ltd.
He previously worked as the Chief Business Officer at Cambridge Theranostics Ltd.
Postes actifs de Nigel Keith Davis
| Sociétés | Poste | Début |
|---|---|---|
Pronec Ltd.
 Pronec Ltd. Miscellaneous Commercial ServicesCommercial Services Pronec Ltd. engages in the research and experimental development on biotechnology. The company was founded on September 14, 2015 and is headquartered in Wirral, the United Kingdom. | Directeur/Membre du Conseil | 11/12/2015 |
Anciens postes connus de Nigel Keith Davis
| Sociétés | Poste | Fin |
|---|---|---|
Cambridge Theranostics Ltd.
 Cambridge Theranostics Ltd. Pharmaceuticals: GenericHealth Technology Cambridge Theranostics (CTL) was founded in 2002 as a spin-out from Cambridge University, following the discovery of ALOA (Atherogenic Lipid-Oxidising Antibodies) by its founder Dr. Petyaev. It is privately funded. The Company continues to have a very strong research focus and now owns 10 granted patents in Europe, U.S.A, Eurasia and Japan the US, with a further 18 applications pending. They also conduct clinical studies with their partners in Europe, U.S. and Russia. CTL develops specially formulated supplements to provide the correct doses of nutrients in a form that is effective. Its scientists investigate the mechanisms by which nutrients prevent disease and develop highly effective formulations. Together with their clinical partners, they confirm that the nutrient reaches the correct part of the body and is active. | Corporate Officer/Principal | 18/12/2012 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cambridge Theranostics Ltd.
Cambridge Theranostics Ltd. Pharmaceuticals: GenericHealth Technology Cambridge Theranostics (CTL) was founded in 2002 as a spin-out from Cambridge University, following the discovery of ALOA (Atherogenic Lipid-Oxidising Antibodies) by its founder Dr. Petyaev. It is privately funded. The Company continues to have a very strong research focus and now owns 10 granted patents in Europe, U.S.A, Eurasia and Japan the US, with a further 18 applications pending. They also conduct clinical studies with their partners in Europe, U.S. and Russia. CTL develops specially formulated supplements to provide the correct doses of nutrients in a form that is effective. Its scientists investigate the mechanisms by which nutrients prevent disease and develop highly effective formulations. Together with their clinical partners, they confirm that the nutrient reaches the correct part of the body and is active. | Health Technology |
Pronec Ltd.
Pronec Ltd. Miscellaneous Commercial ServicesCommercial Services Pronec Ltd. engages in the research and experimental development on biotechnology. The company was founded on September 14, 2015 and is headquartered in Wirral, the United Kingdom. | Commercial Services |
